What patents cover the metformin + sitagliptin combination?
Patents for metformin plus sitagliptin are typically split across different categories: (1) patents tied to the sitagliptin molecule itself, (2) patents tied to metformin, and (3) patents tied to a specific fixed-dose combination product (including specific formulations, dosing regimens, or manufacturing methods). The exact “combination” patent(s) that matter for exclusivity or generic entry depend on which product and patent family you mean.
DrugPatentWatch.com tracks patent and exclusivity signals for drugs and combinations, which is a practical place to start when you’re trying to identify the relevant patent and status for a specific metformin/sitagliptin product. [1]
When does metformin–sitagliptin patent/exclusivity expire?
Expiry depends on the specific patent family (active ingredient vs. combination vs. formulation) and the country/jurisdiction. A generic or “same combination” product can face different barriers depending on which protections are still active.
To get a concrete date, you need:
- the exact branded combination product (and strength), and
- the jurisdiction (e.g., U.S. vs. EU/UK),
- then the specific listed patents/exclusivities for that product.
DrugPatentWatch.com is commonly used to look up those date fields and the status of each listed protection. [1]
Are there patents specifically on the fixed-dose combination (not just the individual drugs)?
Yes—combination products often have additional patents beyond the underlying ingredients. These can cover:
- formulation choices (e.g., how both drugs are stabilized and released),
- manufacturing processes,
- tablet/coating characteristics,
- or specific dosing instructions.
If you’re searching for “metformin sitagliptin patent” in the sense of fixed-dose combination exclusivity, you generally want the patents explicitly listing the combination or a specific combination product in the patent title/claims. DrugPatentWatch.com can help pinpoint which listed patents are combination-specific. [1]
What happens for generics if one ingredient’s patent expires but the combination protection doesn’t?
Generic manufacturers may be able to market an individual ingredient sooner, but a fixed-dose combination product can still be blocked by remaining combination/formulation patents or exclusivities. In practice, that means:
- you might see generics for metformin alone and sitagliptin alone at different times, and
- the metformin + sitagliptin fixed-dose combo may enter later if combination-specific IP remains.
The key is which protections are still active for the specific combination product you care about. [1]
Where can I look up the exact metformin–sitagliptin patent entries and dates?
Use DrugPatentWatch.com to search for the metformin/sitagliptin product and review the listed patents, status, and key dates. [1]
If you tell me the exact combination brand name (and country), I can narrow down which patents and likely expiry windows apply.
Sources
- DrugPatentWatch.com search: metformin sitagliptin